Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.
about
Hybrid spreading mechanisms and T cell activation shape the dynamics of HIV-1 infectionModeling the within-host dynamics of HIV infectionCell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapyTargeted DNA mutagenesis for the cure of chronic viral infectionsA highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelEpstein-Barr Virus: Diseases Linked to Infection and TransformationHIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamicsModelling HIV and MTB co-infection including combined treatment strategiesModeling the Slow CD4+ T Cell Decline in HIV-Infected IndividualsResidual Viremia in Treated HIV+ IndividualsPharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyCumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDSA model of HIV-1 infection with two time delays: mathematical analysis and comparison with patient data.Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical dataProvirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Impact of latently infected cells on strain archiving within HIV hosts.Reduced evolutionary rates in HIV-1 reveal extensive latency periods among replicating lineagesQuantifying the turnover of transcriptional subclasses of HIV-1-infected cellsHerpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.T cell state transition produces an emergent change detector.Immuno-modulatory strategies for reduction of HIV reservoir cells.Post-treatment control of HIV infection.HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.An evolutionary role for HIV latency in enhancing viral transmission.Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.Recombination Enhances HIV-1 Envelope Diversity by Facilitating the Survival of Latent Genomic Fragments in the Plasma Virus Population.Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infectionState-transition diagrams for biologistsPrecise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.Effect of the Latent Reservoir on the Evolution of HIV at the Within- and Between-Host Levels.A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.Contribution of follicular dendritic cells to persistent HIV viremia.GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell deathInvestigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsSpatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.
P2860
Q21092519-1F465113-1745-41FF-B0F0-20165CB2E578Q21245370-C4E0CB58-D8EF-4929-AB07-9A78F265F34DQ22251085-5A6987CB-2851-4DA4-87EC-9B6540300137Q24620150-DF41EFB0-B0E5-4B16-AEA0-5873341E833AQ27344720-EF68C66E-3C01-445C-B5C2-3282FE5620D4Q28074586-34EFCC15-157E-4FC9-A529-72252CCCD4F0Q28481343-828F4145-0CBD-4C3A-B7FA-6DEBA201DDB4Q28485357-8D9AC0AF-B8FA-488B-90EF-7EF946C082ECQ28551803-FB759B6A-74DC-4589-B5FD-9289D707D82FQ28552126-EF715D65-76A7-4AA5-8577-38E438C30E9BQ33827819-82C4850C-FF10-4360-BAD6-BBD91F06305EQ33916321-7E9717CF-C636-4DE3-B80E-3C2317204835Q34080406-A35C562B-5C92-4492-84B2-CFF0AA965C8BQ34131596-1786CFEB-60FC-4B37-859B-413922294E1EQ34218827-1010F9D4-6AE8-4717-8AAB-F8DD8FD93B6BQ34331710-53033E30-9CE7-438C-BDBA-74B17AEBA12BQ34362894-08E16D4F-4E42-4D87-91AF-E2483406D6B1Q34393716-E1EE24C3-21DE-45B3-A8E8-01935D617DA5Q34464387-33BE6516-135E-451E-9456-245D84C84555Q34562253-D8211E2B-34F2-477E-866E-5B813A789DC2Q34572554-260AA7E9-81FA-4B0F-92B5-091DDB9246A4Q34573789-9B23D5CF-27DE-429F-9CE4-E4D6AEB616C0Q34632299-5B4A3E59-E4FC-4AB7-B2A5-5F7CC7FC40BDQ35329923-BBAE6258-84B2-4597-806C-FB3E19D6870EQ35567047-5E64BCAA-A80E-4DDF-8C05-092CE4B7D58EQ35680431-FA9AE11D-CD11-4979-9532-83EE3E59AEE7Q35807225-D972C33A-9222-4288-8AAE-6F54F3B83459Q35819184-97A1F636-AC89-4F4E-B1BC-6EB12A547413Q35875253-1B036BCF-43C6-4948-A68D-309ECEA238E5Q36066494-3C644271-3E9B-4C7F-9DC1-15433326A5EDQ36109844-9BE0CEB6-9D2D-4E0E-BCC2-862EAA06540DQ36148964-6C94D732-0655-4EA6-942F-657FB66E57BFQ36253793-68BFF36A-26BF-4208-AC26-7F4CE302A4A3Q36387986-AF7A36C2-EDA3-4BD4-A271-D3EED9267C11Q36978662-7534CEB5-0D83-4085-9EE2-B2EE2627F8C9Q37007606-AC3D2528-9591-4CDF-BE4D-9ED6A29D164FQ37109010-672C488A-BEC7-4801-80E9-17D87CA3F0C9Q37273652-6B25D11B-A75D-4144-8143-85C7BFF8C806Q37621893-228B1E00-5175-40CC-9F41-2A24D4A3A706Q38078562-5DB2E682-B9A9-4193-9EF5-66F28D11C5A3
P2860
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Modeling latently infected cel ...... ed patients on potent therapy.
@ast
Modeling latently infected cel ...... ed patients on potent therapy.
@en
Modeling latently infected cel ...... ed patients on potent therapy.
@nl
type
label
Modeling latently infected cel ...... ed patients on potent therapy.
@ast
Modeling latently infected cel ...... ed patients on potent therapy.
@en
Modeling latently infected cel ...... ed patients on potent therapy.
@nl
prefLabel
Modeling latently infected cel ...... ed patients on potent therapy.
@ast
Modeling latently infected cel ...... ed patients on potent therapy.
@en
Modeling latently infected cel ...... ed patients on potent therapy.
@nl
P2860
P1476
Modeling latently infected cel ...... ed patients on potent therapy.
@en
P2093
Libin Rong
P2860
P304
P356
10.1371/JOURNAL.PCBI.1000533
P577
2009-10-16T00:00:00Z